secwatch.observer — SEC 8-K summary
======================================

Issuer:     NANOVIRICIDES, INC. (NNVC)
CIK:        0001379006
Form:       8-K
Filed at:   2021-09-15T23:59:59+00:00
Accession:  0001104659-21-115943
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash
-----------------------------------------------------------------------------

- Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.
- Milestone payments include up to 750,000 Series A preferred shares and up to $11M in cash tied to clinical development.
- Royalty of 15% on net sales of licensed products; TheraCour retains manufacturing rights.
- President Anil Diwan's employment extended to June 30, 2022 with $400K base salary and 10,204 Series A shares vesting quarterly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/0001104659-21-115943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/tm2127721d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-115943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer